Answer
Women of childbearing potential should use effective contraception during tafasitamab treatment and for at least 3 months after treatment ends.
Sources for this answer
- MINJUVI 200 mg powder for concentrate for solution for infusionIncyte Biosciences UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 13Document updated
Sources checked